Tagged Articles

Xigduo 3 articles

European regulators to review serious metabolic side effects with diabetes drugs

The European Medicines Agency (EMA) announced it will review the risk of a life threatening metabolic condition known as ketoacidosis from the use of certain type 2 diabetes drugs known as SGLT2 inhibitors. The review comes just after the U.S. Food and Drug Administration (FDA) ordered that warnings be placed on the labels of SGLT2 drugs advising patients and doctors of this risk. Ketoacidosis is a serious diabetes complication where the body produces excess blood acids, or ketones. It can lead to diabetic coma or death. It generally occurs when insulin levels are too low or during prolonged fasting. However, ... Read More

FDA approves new type 2 diabetes treatment

The Food and Drug Administration (FDA) has approved Xigduo, a new once-daily treatment for type 2 diabetes. Xigduo is a combination of an extended release version of the long-used diabetes drug metformin and dapagliflozin, a diabetes drug recently approved by the FDA and marketed under the name Farxiga. Xigduo is the first and only once-daily combination oral medication of an SGLT2 inhibitor and an extended release version of metformin to be approved in the United States. The drug is intended to be used in combination with exercise and diet to improve glycemic control in adults with type 2 diabetes. The ... Read More

Europe approves new combination diabetes treatment despite bladder cancer concerns

European drug regulators have approved AstraZeneca and Bristol-Myers Squibb’s combination type 2 diabetes drug Xigduo, making it the first treatment to combine a SGLT2 inhibitor with metformin. Xigduo is a combination of the widely used diabetes drug metformin and dapagliflozin, a new diabetes treatment sold in Europe as Forxiga. It was approved earlier this month by the U.S. Food and Drug Administration (FDA) under the name Farxiga. Dapagliflozin is in a new class of diabetes drugs known as SGLT2 inhibitors. Johnson & Johnson’s SGLT2 Invokana was approved in the U.S. in 2013. Other SGLT2 drugs are currently in development. The ... Read More